| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
1033.45(B) |
| Last
Volume: |
2,468,201 |
Avg
Vol: |
3,382,424 |
| 52
Week Range: |
$625.65 - $1109.94 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 19.5 |
| Insider 3/6 Months : 20.1 |
|
| Guru Rank Number : 412 |
| Guru Rank Value : 5.2 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
6,987 |
6,987 |
6,987 |
| Total Buy Value |
$0 |
$4,537,301 |
$4,537,301 |
$4,537,301 |
| Total People Bought |
0 |
8 |
8 |
8 |
| Total Buy Transactions |
0 |
8 |
8 |
8 |
| Total Shares Sold |
2,505,155 |
3,687,405 |
4,570,655 |
7,440,464 |
| Total Sell Value |
$2,147,483,647 |
$2,147,483,647 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
2 |
3 |
4 |
5 |
| Total Sell Transactions |
26 |
36 |
48 |
90 |
| End Date |
2025-10-05 |
2025-07-04 |
2025-01-03 |
2024-01-04 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lilly Endowment Inc |
|
– – • |
2025-12-29 |
4 |
S |
$1,085.04 |
$3,898,531 |
D/D |
(3,593) |
92,190,516 |
|
0% |
|
| Lilly Endowment Inc |
|
– – • |
2025-12-24 |
4 |
S |
$1,085.17 |
$2,852,920 |
D/D |
(2,629) |
92,194,109 |
|
0% |
|
| Lilly Endowment Inc |
|
– – • |
2025-12-23 |
4 |
S |
$1,085.04 |
$260,409 |
D/D |
(240) |
92,196,738 |
|
-0% |
|
| Greene Gabrielle E |
Director |
– • – |
2025-12-15 |
4 |
A |
$1,062.19 |
$4,958 |
D/D |
5 |
2,957 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2025-12-15 |
4 |
A |
$1,062.19 |
$9,917 |
D/D |
9 |
75,101 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2025-12-15 |
4 |
A |
$1,062.19 |
$14,833 |
D/D |
14 |
16,741 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2025-12-15 |
4 |
A |
$1,062.19 |
$11,750 |
D/D |
11 |
55,468 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2025-12-15 |
4 |
A |
$1,062.19 |
$9,917 |
D/D |
9 |
2,253 |
|
- |
|
| Bertozzi Carolyn R |
Director |
– • – |
2025-12-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,000 |
|
8% |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-25 |
4 |
S |
$1,108.71 |
$17,340,625 |
D/D |
(15,632) |
92,196,978 |
|
3% |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-25 |
4 |
S |
$1,073.74 |
$161,082,640 |
D/D |
(147,061) |
92,212,610 |
|
3% |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-21 |
4 |
S |
$1,050.27 |
$111,504,098 |
D/D |
(105,326) |
92,501,978 |
|
-1% |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-20 |
4 |
S |
$1,050.36 |
$39,067,117 |
D/D |
(37,148) |
92,607,304 |
|
-3% |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-19 |
4 |
S |
$1,050.21 |
$176,098,702 |
D/D |
(167,526) |
92,644,452 |
|
-2% |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-18 |
4 |
S |
$1,030.32 |
$62,306,969 |
D/D |
(60,213) |
92,811,978 |
|
-4% |
|
| Fyrwald J Erik |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$229,916 |
D/D |
225 |
74,989 |
|
- |
|
| Kaelin William G Jr |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$220,000 |
D/D |
215 |
21,837 |
|
- |
|
| Baicker Katherine |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$220,000 |
D/D |
215 |
23,503 |
|
- |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-17 |
4 |
S |
$1,030.45 |
$10,189,269 |
D/D |
(9,886) |
92,872,191 |
|
-5% |
|
| Hedley Mary Lynne |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$229,916 |
D/D |
225 |
2,241 |
|
- |
|
| Johnson Kimberly H |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$220,000 |
D/D |
215 |
3,265 |
|
- |
|
| Jackson Jamere |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$220,000 |
D/D |
215 |
9,635 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$234,833 |
D/D |
230 |
16,704 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$224,958 |
D/D |
220 |
2,948 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$231,749 |
D/D |
227 |
55,379 |
|
- |
|
1458 Records found
|
|
Page 1 of 59 |
|
|
5.68 (0.53%) 
